Raymond James initiated coverage of Knight Therapeutics with an Outperform rating and C$7 price target. After spending the last four years consolidating its acquisition of Grupo Biotoscana, Knight Therapeutics has now established the platform onto which it can onboard new drugs, benefiting from significant operating leverage, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KHTRF:
- Knight Therapeutics Inc. Celebrates its First Decade of Success
- Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil
- Knight Therapeutics announces launch of Bijuva in Canada
- Knight Therapeutics Announces Launch of Bijuva® in Canada
- Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203
